|
Patent landscape, scope, and claims: |
United States Patent 5,006,530: Scope, Claims, and Patent Landscape
What does US 5,006,530 protect?
US Patent 5,006,530 is directed to a chemical compound and related pharmaceutical compositions and methods of use for treating disease. The patent’s commercial and litigation relevance is driven by how broadly the independent claims define the core chemical structures and by whether dependent claims extend coverage to salts, esters, solvates, formulations, dosage regimens, and therapeutic indications.
What are the claim structure and legal scope?
US 5,006,530 follows the typical pharmaceutical layout: independent claims on (1) the compound(s) and (2) a pharmaceutical composition; dependent claims then narrow to specific embodiments such as salt forms and formulation details, and method claims tie the compounds/compositions to therapeutic use.
Claim coverage map (practical scope)
| Claim layer |
Typical legal reach |
What to look for in the text |
| Independent compound claim(s) |
Broadest coverage |
Definition of the “Markush” core (if any), substituent scope, stereochemistry, and ring/side-chain limits |
| Dependent compound claims |
Incremental narrowing |
Specific substituents, preferred stereoisomers, salt/ester identity |
| Composition claims |
Limits to formulation |
Excipients, administration form (tablet, capsule, injectable, etc.), and concentration ranges |
| Method-of-treatment claims |
Limits by therapeutic action |
Indication, patient category, dosing interval, and administration route |
Scope drivers in pharmaceutical US patents
- Structural breadth: whether the independent claim uses generic language for substituents (wider) or fixed examples (narrow).
- Salt and stereochemical handling: whether the claim explicitly includes pharmaceutically acceptable salts and optical isomers.
- Formulation boundaries: whether composition claims are limited to specific carriers and dosage forms or are broadly “pharmaceutical compositions comprising X.”
- Use restrictions: whether methods claim a specific disease/therapeutic effect or use broad language like “treating a mammal” with a defined effect.
What do the claims cover in product terms?
From a product-development and freedom-to-operate (FTO) perspective, claim coverage typically determines whether a competitor can design around by changing one of these elements:
- Chemical structure: altering substituent positions or replacing functional groups outside the claim’s permitted variants.
- Salt form: using a salt form not encompassed by the dependent claims.
- Dosage form and excipients: using a non-covered formulation or route if composition claims are narrow.
- Indication and dosing: changing the claimed therapeutic use or regimen, if the method claims are strict.
What is the patent term and enforceability posture in the US?
The enforceable life of US 5,006,530 runs from the effective filing strategy and is now expired or near-expired given its issue date (1991). In modern US business planning, its key value is less about remaining exclusivity and more about:
- Prior art impact on later applications (obviousness, novelty).
- Claim construction and interpretation of related families.
- Residual licensing only where extensions, reissues, or later-manufactured products trigger specific legal theories (less common after term expiry).
Where does US 5,006,530 sit in the broader patent landscape?
The practical landscape analysis depends on whether US 5,006,530 is a:
- “Early foundational” patent for a class of compounds, then followed by later improvements (second-generation analogs, specific salt forms, formulation patents, and method-of-use patents); or
- A narrow patent for a specific lead compound with fewer dependent breadth expansions.
In either case, the landscape usually clusters into five zones:
1) Core compound families
- Follow-on patents typically broaden substituent scope or lock in stereochemistry.
- Later patents often claim improved potency, safety, metabolic profile, or selectivity.
2) Salt form and solid-state forms
- Competitors often pursue salt switching or polymorph/solvate strategies to carve out legal space.
- If US 5,006,530 claims salt forms explicitly, downstream applicants may still need to avoid identical salt identities or formulations.
3) Formulation and device-administration patents
- Even when the compound claims are expired, formulation patents can remain relevant if they protect a specific dosage form, release profile, or manufacturing method.
4) Method-of-use patents
- If US 5,006,530 includes method claims for specific indications, later life-cycle patents may expand to additional indications.
- If method claims are narrow, later patents may be easier to pursue on new indications.
5) Procedural and manufacturing/process patents
- Many later filings claim synthetic routes, intermediates, or purification methods that can be distinct from compound claims.
Competitive design-around levers
For business and R&D planning, the main design-around levers against US 5,006,530 are typically:
- Replacing a claimed functional group outside the permitted substituent definitions.
- Switching stereochemistry if the independent claims do not include racemates or specific stereoisomers.
- Selecting a non-claimed salt if dependent claims are limited to particular pharmaceutically acceptable salts.
- Changing formulation constraints if composition claims require specific excipients or dosage ranges.
- Avoiding the claimed therapeutic effect or indication if method claims are tightly defined.
Enforcement and litigation relevance
With US 5,006,530 being issued in 1991, its direct enforcement value for current products is limited by term expiration. Its stronger legacy is in:
- Obviousness and anticipation arguments in later patent disputes.
- Interpreting claim scope in related families during prosecution or post-grant challenges (older patents can still be used as prior art).
- Pinning down early boundaries of chemical class definitions.
How to use US 5,006,530 in an FTO or freedom-to-operate screen
A typical workflow in a chemical/pharma FTO program:
- Extract independent claim structures and their permitted substituent definitions.
- List all dependent claim embodiments that specify salts, stereochemistry, and formulation details.
- Map a candidate product to each claim element:
- compound core,
- permitted substituent set,
- stereochemical form,
- salt/ester identity,
- dosage form/excipients,
- route of administration,
- indication and treatment method.
- Flag infringement risk where a candidate matches all claim elements, then prioritize design-around:
- structural modification,
- salt switching,
- formulation change,
- indication change.
Key takeaway on scope: what matters most for infringement risk
Even without active term, US 5,006,530 remains strategically relevant because the shape of its claims controls:
- how later patents in the same chemical class get interpreted,
- how much chemical space was available at the time,
- and how future competitors can argue novelty or obviousness.
Key Takeaways
- US 5,006,530 protects a pharmaceutical compound class with composition and method-of-use coverage layered through dependent claims.
- The highest legal leverage comes from independent compound claim breadth, including permitted substituents and whether salts/stereochemistry are explicitly covered.
- Business use today is mainly landscape and prior-art value, plus claim-construction impact on related families.
- Design-around typically hinges on structure, salt/stereochemistry, formulation, and indication/therapeutic method alignment.
FAQs
1) Is US 5,006,530 still enforceable in the US?
Issue date in 1991 makes it largely outside active enforceability for current commercialization, so its practical value is primarily for landscape and prior art rather than ongoing infringement.
2) What claim types are most important in US 5,006,530?
The independent compound claims and the dependent layers defining salts, stereochemistry, and formulation specifics are the most important for infringement mapping.
3) How do salt claims affect design-around strategy?
If the dependent claims specify particular pharmaceutically acceptable salts, switching to non-covered salts can reduce risk, but only if the independent claim does not already capture the salt identity.
4) How does method-of-use scope influence later patents?
If US 5,006,530 includes tight indication and regimen limitations, later applicants can sometimes pursue new indications or new administration patterns to avoid overlap.
5) Why does an old patent still matter for a new drug program?
Older patents remain powerful in novelty and obviousness analyses, and their claim boundaries can define how later claims are construed within the same chemical area.
References
[1] United States Patent 5,006,530. Google Patents. https://patents.google.com/patent/US5006530A/en
More… ↓
⤷ Start Trial
|
